Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates

NCT ID NCT06973161

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal is to see if T-DXd helps patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Trastuzumab deruxtecan (T-DXd)

What this could lead to

If successful, this could provide stronger evidence that T-DXd is more effective than standard treatments for several HER2-positive cancers.

What could go wrong

This is a retrospective study using existing data, not a new trial. Results may be less reliable than a randomized controlled trial, and differences in patient groups could skew comparisons.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cervical cancer colorectal adenocarcinoma colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma pancreatic neoplasm urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BLADDER CANCER CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER LUNG CANCER OTHER TUMORS OVARIAN CANCER PANCREATIC CANCER

Contacts and locations

Locations

  • Research Site

    Spartanburg, South Carolina, 29303, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Vienna, Austria

  • Research Site

    Liège, Belgium

  • Research Site

    London, Ontario, N6A 5A5, Canada

  • Research Site

    Olomouc, Czechia

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Caen, France

  • Research Site

    Lille, France

  • Research Site

    Marseille, France

  • Research Site

    Nice, France

  • Research Site

    Paris, France

  • Research Site

    Saint-Herblain, France

  • Research Site

    Berlin, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Meldola, Italy

  • Research Site

    Rome, Italy

  • Research Site

    Porto, Portugal

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Leeds, United Kingdom

  • Research Site

    London, United Kingdom